LLY Q3 2025: Revenue Up 54% — Guidance Raised

Published: October 30, 2025

ELI LILLY & Co

Direct News

Revenue up 54% year-over-year in Q3 2025 (company announcement).
Eli Lilly raised full-year guidance following Q3 results.
Net income for the nine months ended Sept. 30, 2025: $14,002.3M (filed).
Total assets as of Sept. 30, 2025: $114,935.4M; long-term debt: $40,873.6M; shareholders' equity: $23,793.3M (filed).
Shares outstanding approximately 946M as of Sept. 2025.
Share repurchase program: $15B authorized (Dec 2024); $12.4B remaining as of Sept. 2025.
Anti-obesity products (e.g., Zepbound) are a significant portion of revenue per company filings.

Historical Context

Eli Lilly, founded in 1876 and headquartered in Indianapolis, operates globally across cardiometabolic, oncology and immunology therapeutic areas and maintains collaborations with companies such as Boehringer Ingelheim, Incyte and Roche/Genentech (company profile). Quarterly filings through 2025 show balance-sheet movement: total assets rose from $100,922.6M at June 30, 2025 to $114,935.4M at Sept. 30, 2025. Share counts reported were ~948M in Feb. 2025 and ~946M in Sept. 2025. The company authorized a $15B share repurchase program in Dec. 2024; $12.4B remained as of Sept. 2025. Filings also document debt issuances in 2025 (including floating-rate SOFR-linked notes and fixed-rate notes maturing 2028–2032). On innovation and pipeline: filings reference tirzepatide programs (Zepbound/Mounjaro) and other pipeline priorities (weekly insulin candidates, lebrikizumab in immunology), along with major manufacturing investments (Lilly Medicine Foundry and Lebanon site expansion). Management priorities inferred from filings include accelerating innovation, expanding manufacturing and patient access, and corporate governance and sustainability initiatives. These historical elements frame the Q3 2025 results: strong top-line momentum driven by concentrated product performance, supported by capacity investments and an active capital-return program, but set against disclosed legal, regulatory and competitive risks.

What drove the 54% revenue surge

Eli Lilly's reported 54% year-over-year revenue growth in Q3 2025 is consistent with the company's stated concentration of revenue in cardiometabolic and anti-obesity therapies. Filings and the company profile identify tirzepatide (Mounjaro/Zepbound) and other diabetes/obesity products (Jardiance, Trulicity, insulin franchises) as major contributors. The company also lists oncology and immunology products among its commercial portfolio, but anti-obesity and cardiometabolic medicines are highlighted as significant revenue drivers. Management linked the strong top-line performance to accelerating demand for key products and ongoing commercialization efforts (including LillyDirect for direct-to-consumer access). The firm has been expanding manufacturing capacity — including large investments in the Lilly Medicine Foundry and site expansions — to support growth, a factor that supports near-term supply but also raises capital intensity.

Guidance raise and balance-sheet context

Following the quarter, Eli Lilly raised full-year guidance, signaling management's confidence in sustained demand. On a balance-sheet basis, filings through Sept. 30, 2025 show growing assets ($114,935.4M) and net income through nine months of $14,002.3M. Long-term debt stands at $40,873.6M, and the company recently issued several debt instruments (including floating-rate notes and fixed-rate notes maturing in 2028–2032 per filings). Investors should note the company is actively returning capital: a $15B repurchase program was authorized in Dec. 2024, with $12.4B remaining as of Sept. 2025. Shares outstanding were approximately 946M at Sept. 2025, indicating share-count trends that affect per-share metrics.

Investor implications and key risks

The reported 54% revenue growth and guidance raise are materially positive for revenue momentum, but filings emphasize concentration risk. A significant share of revenue derives from a few products, notably anti-obesity and diabetes therapies, which heightens exposure to regulatory, reimbursement and patent/timelines risk. The company's own moat assessment notes the absence of a clear structural moat: patent exclusivity is temporary, and generic or biosimilar entry can rapidly erode revenue once exclusivity expires. Other risk factors disclosed in filings include litigation and regulatory investigations, R&D and approval uncertainties, pricing and reimbursement pressures (including employer coverage decisions for anti-obesity medications), supply-chain and third-party dependencies, and macroeconomic and geopolitical risks. Operational and execution risks accompany large manufacturing investments and business-development activities. Investors should weigh strong near-term growth against these concentration and competitive risks documented in the company's filings.

Investor FAQ

The most effective approach is to maintain a factual perspective. Keep a close watch on further developments at ELI LILLY & Co as they unfold. Use primary source data to validate your investment thesis rather than relying on delayed secondary reports.

You can set up an automated tracker on Portrak. Our system monitors official SEC filings in real-time, delivering the most critical insights to your phone or inbox seconds after publication—frequently before the information reaches major financial news platforms.

We believe quality intelligence should be accessible. Our business model is supported by professional investors with large, complex portfolios who utilize Portrak Pro. These users pay to automate the monitoring of extensive watchlists, saving hundreds of hours in research time, which allows us to keep the standard service free for individual investors tracking their core positions.

Setting up your automated intelligence pipeline is a simple 3-step process:

Create Your Free Account

Select Your Focus

Use the search bar to find companies like ELI LILLY & Co. Choose between monitoring specific events or receiving general market-moving intelligence. Our AI automatically determines what’s critical based on real-time market data and the company’s current profile.

Receive Real-Time Intelligence

Once activated, all official filings are analyzed instantly. Insights are delivered directly to your email or as a push notification if you use the Portrak mobile app.

Also available as a mobile app for iOS & Android—search for "Portrak"

More Strategic Insights

LLY

Oct 30, 2025

Direct News

Historical Context

What drove the 54% revenue surge

Guidance raise and balance-sheet context

Investor implications and key risks

Investor FAQ

More Strategic Insights

LLY: Eli Lilly Reports Key FDA Approvals

LLY Dividend Q3 2025: Raised 15% to $1.50

LLY: Eli Lilly Advances Biotech Acquisitions

LLY: Eli Lilly Divests Cialis Rights Abroad